BioHarvest Sciences (BHST)
NASDAQ:BHST
Want to see BHST full AI Analyst Report?
Earnings Data
Report Date
Aug 31, 2026TBA (Not Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.24Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed solid technological and commercial progress — notable CDMO milestones (Stage 1 completions, a $1.2M Stage 2 fragrance contract with 20% retained ownership, and Saffron Stage 1 advancement), stronger cash position, and clear D2C product traction (VINIA Blood Flow Hydration, strong reviews, active users). However, near-term financials show continued net losses, increased operating and marketing spend, and a deliberate D2C marketing reset that temporarily depressed revenue. Execution risks remain around manufacturing capacity timing (new facility target H2 2027), potential future capital needs, and early-stage validation for novel assets. Overall the positives (milestones, cash build, pipeline, product traction and reiterated guidance) outweigh the short-term headwinds and uncertainties, but successful execution over the next quarters — especially H2 2026–2027 — will be critical to realize the opportunities.Company Guidance
Quarterly Revenue Growth
Total revenue for Q1 2026 was $8.5M, up 8% year-over-year from $7.9M in Q1 2025.
Improved Gross Margin
Gross profit was $5.0M, representing a 59% gross margin versus $4.6M and 58% in the year-ago quarter (≈ +1 percentage point).
Significant Cash Position Improvement
Cash, cash equivalents and bank deposits increased to $20.2M as of March 31, 2026, from $3.4M a year earlier (increase of $16.8M, ≈ +494%).
CDMO Technological and Commercial Milestones
Completed Stage 1 stable cell culture of a rare scent-producing plant and signed a Stage 2 contract for the fragrance program worth $1.2M; BioHarvest retains 20% ownership of compositions, creating a potential long-term royalty stream.
Saffron Program Advancement
Completed Stage 1 with Saffron Tech and advanced to Stage 2 after creating a stable saffron cell bank demonstrating key saffron actives (crocin, picrocrocin, safranal); planned production timing aligned with new facility capacity (targeted second half of 2027) and nutraceutical go-to-market expected as a dietary supplement.
CDMO Revenue Guidance and Pipeline
Reiterated 2026 total CDMO revenue guidance (including intercompany VINIA production) of $12M–$14M and additional project-driven revenue of $4M–$6M from a combination of existing and new projects; management expects 3–4 new projects in the near-term pipeline.
VINIA D2C Traction and Product Momentum
VINIA has >90,000 active users and cumulative VINIA-based sales near $100M; VINIA Blood Flow Hydration reached ~ $1M in sales since late November launch, is the #2 contributor to incremental new-customer sales (20% of new-customer revenue YTD on vinia.com and Amazon), and has an average rating of 4.7/5 across ~160 verified reviews.
D2C 2026 Guidance
D2C revenue guidance for 2026 remains $38M–$42M with projected adjusted EBITDA profit of $0.5M–$2M.
Adjusted EBITDA Stability
Company reported an adjusted EBITDA loss of $1.2M for Q1 2026, in line with the prior-year period; CDMO adjusted EBITDA loss improved to $904K from $953K year-over-year (≈ -5.1%).
BHST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BHST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | $4.00 | $4.16 | +3.87% |
Mar 31, 2026 | $4.34 | $4.31 | -0.69% |
Nov 13, 2025 | $7.30 | $7.23 | -0.96% |
Aug 11, 2025 | $8.76 | $8.82 | +0.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioHarvest Sciences (BHST) report earnings?
BioHarvest Sciences (BHST) is schdueled to report earning on Aug 31, 2026, TBA (Not Confirmed).
What is BioHarvest Sciences (BHST) earnings time?
BioHarvest Sciences (BHST) earnings time is at Aug 31, 2026, TBA (Not Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BHST EPS forecast?
BHST EPS forecast for the fiscal quarter 2026 (Q2) is -0.12.